Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 4, 2009, Pages 417-424

  Price, David ^a   Sharma, Ashish ^b   Cerasoli, Frank ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c PFIZER INC   (United States)

Author keywords

FEV1; HRQL; Metabolism; Pharmacokinetics; Tiotropium

Indexed keywords

IPRATROPIUM BROMIDE; MUSCARINIC M3 RECEPTOR; PLACEBO; TIOTROPIUM BROMIDE;

ANTICHOLINERGIC EFFECT; BREATHING MUSCLE; CHEMICAL ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HEART RATE; HUMAN; LUNG FUNCTION; MORBIDITY; MORTALITY; NONHUMAN; RECEPTOR BINDING; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SMOOTH MUSCLE RELAXATION; URINE RETENTION; XEROSTOMIA;

ADMINISTRATION, INHALATION; ANIMALS; BRONCHODILATOR AGENTS; HUMANS; PROTEIN BINDING; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, MUSCARINIC; SCOPOLAMINE DERIVATIVES;

EID: 67649300729     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902828337     Document Type: Review

References (31)

1. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (COPD). National Heart Lung and Blood Institute/World Health Organization. Available from: www.goldcopd com, 2007. Available from: www.goldcopd.com [Last accessed 4 March 2008]
2. Rudolf M. The reality of drug use in COPD: the European perspective. Chest 2000;117:29S-32S (Pubitemid 30111561)
3. Barnes PJ. Managing chronic obstructive pulmonary disease. London: Science Press, 1999
4. de Jongste JC, Jongejan RC, Kerrebijn KF. Control of airway caliber by autonomic nerves in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1991;143:1421-1426
5. Disse B, Rominger K, Serby CW, et al. The pharmacokinetic (PK) profile of tiotropium during long-term treatment in stable COPD. Am J Respir Crit Care Med 1999;159:A524
6. Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva™): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64:457-464 (Pubitemid 29066693)
7. Barnes PJ. Mechanisms in COPD. Differences from asthma. Chest 2000;117:10S-4S
8. Takahashi T, Belvisi MG, Patel H, et al. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994;150:1640-1645 (Pubitemid 24361740)
9. Chodosh S, Flanders JS, Kesten S, et al. Effective delivery of particles with the HandiHaler® dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med 2001;14:309-315 (Pubitemid 32802033)
10. Voshaar T, Lapidus R, Maleki-Yazdi R, et al. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respir Med 2008;102:32-41
11. van Noord JA, Cornelissen PJ, Aumann JL, et al. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med 2009;103:22-29
12. Türck D, Weber W, Sigmund R, et al. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. J Clin Pharmacol 2004;44:163-172 (Pubitemid 38114315)
13. US food and drug administration. Spiriva HandiHaler (Tiotropium Bromide) inhalation powder. Center for drug evaluation and Research, 2008. Available from: http://www.fda.gov/cder/ foi/nda/2004/21-395-Spiriva.htm [Last accessed 5 December 2008]
14. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-224 (Pubitemid 34162820)
15. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-1554
16. Maesen FPV, Smeets JJ, Sledsens TJH, et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1506-1513
17. Postma DS, Keyzer JJ, Koeter GH, et al. Influence of the parasympathetic and sympathetic nervous system on nocturnal bronchial obstruction. Clin Sci 1985;69:251-258 (Pubitemid 15246104)
18. Celli B, Zuwallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003;124:1743-1748 (Pubitemid 37433567)
19. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005;128:1168-1178 (Pubitemid 41324392)
20. Verkindre C, Bart F, Aguilaniu B, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006;73:420-427 (Pubitemid 43909741)
21. Rice KL, Kunisaki KM, Niewoehner DE. Role of tiotropium in the treatment of COPD. Int J Chron Obstruct Pulmon Dis 2007;2:95-105
22. Chen AM, Bollmeier SG, Finnegan PM. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease. Ann Pharmacother 2008;42:1832-1842
23. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130:1695-1703 (Pubitemid 46033421)
24. Boehringer Ingelheim, Pfizer. Spiriva HandiHaler (tiotropium bromide inhalation powder): prescribing information. Available from: www spiriva com, 2008. Available from: http://www.spiriva.com/hcp/index.jsp [Last accessed 5 December 2008]
25. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-1450
26. de Luise C, Lanes SF, Jacobsen J, et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol 2007;22:267-272 (Pubitemid 46733877)
27. Jara M, Lanes SF, Wentworth C III, et al. Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf 2007;30:1151-1160 (Pubitemid 350172856)
28. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-1505 (Pubitemid 24986688)
29. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166:333-339
30. Lanes S, Golisch W, Mikl J. Ipratropium and lung health study. Am J Respir Crit Care Med 2003;167:801-802
31. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555 (Pubitemid 47403272)